Vaccination response for immunodeficiency disorders or high cortisol
A method of improving a human's response to vaccination with a vaccine enhancement food. This food contains at least transfer factor and lactic acid generating bacteria, and in some embodiments includes glucans. The vaccine enhancement food may be consumed before, during, or after the vaccination. The results are an improvement in the vaccine titer, a slower decay of titer, longer periods of immunity, and fewer needed boosters.
1. A method of increasing the antibody production of a vaccine for a mammal, comprising:
administering a transfer factor formulation comprising at least transfer factor to the mammal before, during, or after the vaccine is administered, wherein each dosage is present at 0.05 to 50 mg per pound of the mammal's body weight and the formulation is into a solution for injection, into a food for consumption, or into a liquid for consumption, and wherein more antibodies are created by the vaccine plus formulation than are created by the vaccine without the formulation.
2. The method of claim 1 wherein the transfer factor formulation further comprises lactic acid generating bacteria.
3. The method of claim 2 wherein the lactic acid generating bacteria in each dosage is present at 0.47-10 mg per pound of the mammal's body weight.
4. The method of claim 1 further comprising measuring a vaccine antibody titer to quantify the increasing.
5. The method of claim 4 wherein the antibody titer is specific to any one disease selected from the group consisting of bordetella pertussis, haemophilus influenzae b. neisseria meningitides, poliovirus, streptococcus pneumoniae, tetanus toxoid, diphtheria toxoid, rabies virus, polio, measles, mumps, rubella, and human papillomavirus.
6. The method of claim 1 further comprising administering a booster vaccine within 120 days of the first vaccine.
7. The method of claim 1 wherein the transfer factor formulation further comprises one or more additives selected from the group consisting of glucans, hetero-polysaccharides, vitamins, electrolytes, probiotics, and immune modulators.
8. The method of claim 6 wherein the transfer factor formulation comprises glucans.
9. The method of claim 8 wherein the glucans are derived from mushrooms or hybrid mushrooms.
10. The method of claim 8 wherein the glucans are present at 0.05 to 50 mg per pound of the mammal's body weight.
11. The method of claim 1 wherein the administering occurs 3-30 days before the vaccine is administered.
12. The method of claim 1 wherein the administering continues between five times per day and once per week for 1 to 60 days after the vaccine is administered.
13. The method of claim 12 wherein the administering continues after the 60 days.
14. The method of claim 4 wherein the measuring of the vaccine antibody titer occurs 10-60 days after administration of the vaccine.
15. A method of increasing the antibody production of a vaccine for a mammal, comprising:
preparing a transfer factor formulation, wherein the transfer factor formulation comprises at least transfer factor and lactic acid generating bacteria, wherein the transfer factor in each dosage is present at 0.05 to 50 mg per pound of the mammal's body weight, and the lactic acid generating bacteria in each the dosage is present at 0.47-10 mg per pound of the mammal's body weight;
incorporating the formulation into a solution for injection, into a food for consumption, or into a liquid for consumption; and
administering the formulation to the mammal before, during, or after the vaccine is administered, wherein more antibodies are created by the vaccine plus the transfer factor formulation than are created by the vaccine without the transfer factor formulation.
16. The method of claim 15 wherein the transfer factor formulation further comprises one or more additives selected from the group consisting of glucans, hetero-polysaccharides, vitamins, electrolytes, probiotics, and immune modulators.
17. A method of increasing the antibody production of a vaccine for a mammal with a formulation that includes at least transfer factor, wherein the transfer factor in each dosage is present at 0.05 to 50 mg per pound of the mammal's body weight, comprising:
incorporating the formulation into a solution for injection, into a food for consumption, or into a liquid for consumption; and
administering the formulation to the mammal before, during, or after the vaccine is administered, wherein more antibodies are created by the vaccine plus formulation than are created by the vaccine without the formulation.
18. The method of claim 17 wherein the formulation further comprises glucans or lactic acid generating bacteria.